WellGen, Inc., a biotechnology company using nutrigenomics to discover and develop plant-based wellness products, announced the completion of its Series B financing totaling $3MM. The capital raised from this latest round of financing will provide additional resources for WellGen to begin clinical studies in humans under its Obesity and Inflammation Programs, aimed at developing and bringing to market a variety of new and promising nutritional products on which the company is working. Investors in this round of financing include both new and existing WellGen shareholders.
